AIM ImmunoTech Inc (AIM)
0.441
-0.02
(-4.30%)
USD |
NYAM |
Sep 28, 16:00
0.441
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 21.35M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -20.55% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 126.64 |
| Price to Book Value | 0.7250 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.76% |
Profile
| AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19. |
| URL | https://www.aimimmuno.com |
| Investor Relations URL | http://ir.hemispherx.net/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 30, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19. |
| URL | https://www.aimimmuno.com |
| Investor Relations URL | http://ir.hemispherx.net/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 30, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |